Correlation of cytosine arabinoside-induced increment in growth fraction of leukemic blast cells with clinical response.
D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000378:metabolism; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects*; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D008938:Mitosis / Q000187:drug effects; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014316:Tritium
D004273:DNA, Neoplasm; D003561:Cytarabine; D014316:Tritium; D002955:Leucovorin; D013936:Thymidine; D008727:Methotrexate